JP4427182B2 - 抗原を安定化するための緩衝液 - Google Patents
抗原を安定化するための緩衝液 Download PDFInfo
- Publication number
- JP4427182B2 JP4427182B2 JP2000513148A JP2000513148A JP4427182B2 JP 4427182 B2 JP4427182 B2 JP 4427182B2 JP 2000513148 A JP2000513148 A JP 2000513148A JP 2000513148 A JP2000513148 A JP 2000513148A JP 4427182 B2 JP4427182 B2 JP 4427182B2
- Authority
- JP
- Japan
- Prior art keywords
- buffer
- antigen
- antigen diluent
- diluent
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 127
- 108091007433 antigens Proteins 0.000 title claims abstract description 127
- 102000036639 antigens Human genes 0.000 title claims abstract description 127
- 239000000872 buffer Substances 0.000 title claims abstract description 73
- 230000000087 stabilizing effect Effects 0.000 title abstract description 5
- 239000003085 diluting agent Substances 0.000 claims abstract description 82
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 19
- 238000003018 immunoassay Methods 0.000 claims abstract description 16
- 241000711549 Hepacivirus C Species 0.000 claims description 60
- 238000003556 assay Methods 0.000 claims description 60
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 23
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical group [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 22
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical group SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 18
- 108010010803 Gelatin Proteins 0.000 claims description 16
- 238000001514 detection method Methods 0.000 claims description 16
- 239000008273 gelatin Substances 0.000 claims description 16
- 229920000159 gelatin Polymers 0.000 claims description 16
- 235000019322 gelatine Nutrition 0.000 claims description 16
- 235000011852 gelatine desserts Nutrition 0.000 claims description 16
- 239000001488 sodium phosphate Substances 0.000 claims description 14
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 14
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical group [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 14
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 12
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 claims description 12
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 12
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 8
- 230000003196 chaotropic effect Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000004094 surface-active agent Substances 0.000 claims description 8
- 239000002981 blocking agent Substances 0.000 claims description 6
- 230000009871 nonspecific binding Effects 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 239000002738 chelating agent Substances 0.000 claims description 5
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 5
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 claims description 5
- 229940035024 thioglycerol Drugs 0.000 claims description 5
- 241000251468 Actinopterygii Species 0.000 claims description 4
- 229910021538 borax Inorganic materials 0.000 claims description 4
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 4
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims description 4
- 208000005176 Hepatitis C Diseases 0.000 claims description 3
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 1
- 229940098773 bovine serum albumin Drugs 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 238000000034 method Methods 0.000 description 16
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 9
- 239000007791 liquid phase Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 239000002245 particle Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 239000013060 biological fluid Substances 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000013024 dilution buffer Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241001227713 Chiron Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229950007919 egtazic acid Drugs 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 1
- AAYSIOJYGRABGS-UHFFFAOYSA-N 3-[9-[4-(2,5-dioxopyrrolidin-1-yl)oxycarbonyl-2,6-dimethylphenoxy]carbonylacridin-10-ium-10-yl]propane-1-sulfonate Chemical compound C=1C(C)=C(OC(=O)C=2C3=CC=CC=C3[N+](CCCS([O-])(=O)=O)=C3C=CC=CC3=2)C(C)=CC=1C(=O)ON1C(=O)CCC1=O AAYSIOJYGRABGS-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108700010756 Viral Polyproteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- DTUNJRIAABDUAS-UHFFFAOYSA-N [O-]S(CCC[N+]1=C(C=CC=C2)C2=C(C(OC2=CC=CC=C2)=O)C2=CC=CC=C12)(=O)=O Chemical compound [O-]S(CCC[N+]1=C(C=CC=C2)C2=C(C(OC2=CC=CC=C2)=O)C2=CC=CC=C12)(=O)=O DTUNJRIAABDUAS-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- -1 dimethylacridinium ester Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000006226 wash reagent Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/108331—Preservative, buffer, anticoagulant or diluent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/2525—Stabilizing or preserving
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5970397P | 1997-09-22 | 1997-09-22 | |
| US60/059,703 | 1997-09-22 | ||
| PCT/US1998/019694 WO1999015901A1 (en) | 1997-09-22 | 1998-09-22 | Buffers for stabilizing antigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009123636A Division JP2009180750A (ja) | 1997-09-22 | 2009-05-21 | 抗原を安定化するための緩衝液 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001517799A JP2001517799A (ja) | 2001-10-09 |
| JP2001517799A5 JP2001517799A5 (enExample) | 2006-02-23 |
| JP4427182B2 true JP4427182B2 (ja) | 2010-03-03 |
Family
ID=22024698
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000513148A Expired - Lifetime JP4427182B2 (ja) | 1997-09-22 | 1998-09-22 | 抗原を安定化するための緩衝液 |
| JP2009123636A Withdrawn JP2009180750A (ja) | 1997-09-22 | 2009-05-21 | 抗原を安定化するための緩衝液 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009123636A Withdrawn JP2009180750A (ja) | 1997-09-22 | 2009-05-21 | 抗原を安定化するための緩衝液 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6261764B1 (enExample) |
| EP (1) | EP1021723B1 (enExample) |
| JP (2) | JP4427182B2 (enExample) |
| AT (1) | ATE417275T1 (enExample) |
| AU (1) | AU9498098A (enExample) |
| CA (1) | CA2303165C (enExample) |
| DE (1) | DE69840334D1 (enExample) |
| ES (1) | ES2316171T3 (enExample) |
| WO (1) | WO1999015901A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4428705A1 (de) * | 1994-08-12 | 1996-02-15 | Boehringer Mannheim Gmbh | Rekombinantes Antigen aus der NS3-Region des Hepatitis C Virus |
| DE69840334D1 (de) * | 1997-09-22 | 2009-01-22 | Novartis Vaccines & Diagnostic | Puffern zur stabilizierung von hcv antigenen |
| US20080064108A1 (en) * | 1997-12-10 | 2008-03-13 | Tony Baker | Urine Preservation System |
| US7569342B2 (en) * | 1997-12-10 | 2009-08-04 | Sierra Molecular Corp. | Removal of molecular assay interferences |
| ATE293159T1 (de) | 1999-12-14 | 2005-04-15 | Thermo Biostar Inc | Stabilisierendes verdünnungsmittel für polypeptide und antigene |
| AU2001276703A1 (en) * | 2000-08-01 | 2002-02-13 | International Reagents Corporation | Method of pretreating sample |
| US20030170618A1 (en) * | 2001-02-02 | 2003-09-11 | Chien David Y. | Buffers for stabilizing antigens |
| US20020141970A1 (en) * | 2001-03-05 | 2002-10-03 | Pettit Dean K. | Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
| RU2206095C1 (ru) * | 2001-10-09 | 2003-06-10 | Пермское научно-производственное объединение "Биомед" | ТЕСТ-СИСТЕМА ДЛЯ ОПРЕДЕЛЕНИЯ АНТИТЕЛ К HBs-АНТИГЕНУ И БЛОКАТОР В ТЕСТ-СИСТЕМЕ |
| JP4744298B2 (ja) | 2003-10-28 | 2011-08-10 | 株式会社先端生命科学研究所 | Ｃ型肝炎ウイルスの検出方法 |
| US20050186642A1 (en) | 2004-02-24 | 2005-08-25 | Biocare Medical, Inc. | Immunoassay reagents and methods of use thereof |
| ITMI20040858A1 (it) * | 2004-04-29 | 2004-07-29 | Farma Dev S R L | Anticorpi monoclonali ibridomi metodo migliorato per determinare la proteina ptx3 e kit per detta determinazione |
| CA2616189C (en) * | 2005-07-22 | 2019-03-26 | Progenics Pharmaceuticals, Inc. | Methods for reducing viral load in hiv-1-infected patients |
| BRPI0520505B1 (pt) * | 2005-09-01 | 2015-03-31 | José Luis Nuño Ayalá | Fórmula estabilizadora de vacinas com antígenos vivos para uso em sistemas de vacinação em massa |
| US20080108147A1 (en) * | 2006-11-03 | 2008-05-08 | Tie Wei | Reduction of non-specific binding in immunoassays |
| US20090068635A1 (en) * | 2007-09-06 | 2009-03-12 | Muerhoff Anthony S | Indirectly labelled assay conjugates and methods of preparing and using same |
| JP5221121B2 (ja) * | 2007-12-27 | 2013-06-26 | キヤノン株式会社 | 絶縁膜の形成方法 |
| US20110065108A1 (en) * | 2008-02-01 | 2011-03-17 | Siemens Healthcare Diagnostics Inc. | Urine Transport Medium |
| JP4593665B2 (ja) * | 2008-03-27 | 2010-12-08 | 三洋化成工業株式会社 | ミオグロビン含有水溶液 |
| US9487837B2 (en) | 2008-10-06 | 2016-11-08 | Morehouse School Of Medicine | Exosome-mediated diagnosis of hepatitis virus infections and diseases |
| US10545149B2 (en) * | 2008-10-06 | 2020-01-28 | Morehouse School Of Medicine | Detection of HIV-related proteins in urine |
| EP2446269A1 (en) * | 2009-06-26 | 2012-05-02 | Atlas Antibodies AB | Improvement of immunodetectability |
| JP5827948B2 (ja) * | 2009-08-17 | 2015-12-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ウイルスを単離する方法 |
| HUE033492T2 (en) * | 2009-10-26 | 2017-12-28 | Genentech Inc | Tests for the detection of antibodies specific for therapeutic anti-verb antibodies and their use in anaphylaxis |
| CN102081018A (zh) * | 2009-11-30 | 2011-06-01 | 希森美康株式会社 | 样品的预处理方法及hcv的免疫测定方法 |
| WO2012154983A2 (en) | 2011-05-10 | 2012-11-15 | Biocare Medical, Llc | Systems and methods for anti-pax8 antibodies |
| US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
| JP6004744B2 (ja) * | 2012-05-28 | 2016-10-12 | 栄研化学株式会社 | 検体希釈浮遊液およびそれを含む容器 |
| EP2900265B1 (en) | 2012-09-27 | 2018-05-30 | Biocare Medical, LLC | Anti-uroplakin ii antibodies systems and methods |
| US10429390B2 (en) | 2012-12-18 | 2019-10-01 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
| ES2720483T3 (es) | 2013-02-28 | 2019-07-22 | Biocare Medical Llc | Sistemas y procedimientos de anticuerpos anti p40 |
| US9816997B2 (en) | 2013-10-03 | 2017-11-14 | Biocare Medical, Llc | Anti-SOX10 antibody systems and methods |
| MX2019008970A (es) * | 2017-01-30 | 2019-12-19 | Abay Sa | Ensayos de socio de unión específico de plasmón basados en solución y nanoestructuras metálicas. |
| WO2018226891A1 (en) * | 2017-06-06 | 2018-12-13 | Northwestern University | Trans-interfacial magnetic separation |
| US20230193246A1 (en) * | 2020-03-05 | 2023-06-22 | BioLegend, Inc. | Methods and compositions for detecting targets |
| EP4154002A4 (en) * | 2020-05-21 | 2024-05-01 | The Chinese University Of Hong Kong | Thermodynamically stabilized antibodies for deep immunolabeling and tissue imaging |
| WO2022119937A1 (en) * | 2020-12-03 | 2022-06-09 | Ortho-Clinical Diagnostics, Inc. | Lithium heparin as a blocking agent |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4511502A (en) * | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| FR2556840B1 (fr) | 1983-12-16 | 1987-12-24 | Immunotech Sa | Procede de dosage in vitro des immunoglobulines specifiques d'un ou plusieurs allergenes et reactifs et moyens pour la mise en oeuvre de ce procede |
| US4847081A (en) * | 1984-07-18 | 1989-07-11 | W. R. Grace & Co.-Conn. | Synthetic bovine parainfluenza viral proteins |
| US4658022A (en) * | 1985-08-08 | 1987-04-14 | Molecular Diagnostics, Inc. | Binding of antibody reagents to denatured protein analytes |
| US4737453A (en) | 1984-12-12 | 1988-04-12 | Immunomedics, Inc. | Sandwich immunoassay utilizing a separation specific binding substance |
| JPH073424B2 (ja) * | 1986-03-31 | 1995-01-18 | 日東電工株式会社 | 免疫学的診断試薬 |
| US4678553A (en) * | 1986-07-11 | 1987-07-07 | Ionics, Incorporated | Renaturing reversibly denatured polypeptides and proteins by electrodialysis of solutions thereof in denaturants |
| DE68907996T2 (de) * | 1988-05-11 | 1994-01-05 | Abbott Lab | Verfahren zur Erhöhung der Spezifizität in kompetitiven Immuntests. |
| US5656426A (en) | 1988-08-01 | 1997-08-12 | Chiron Diagnostics Corporation | Functionaized hydrophilic acridinium esters |
| JPH0436185A (ja) * | 1990-03-28 | 1992-02-06 | Kyowa Hakko Kogyo Co Ltd | 融合抗原ポリペプチド |
| JP3269642B2 (ja) * | 1990-06-25 | 2002-03-25 | 財団法人阪大微生物病研究会 | 非Ａ非Ｂ型肝炎ウイルス遺伝子ｃＤＮＡおよび抗原ポリペプチド |
| US5284932A (en) * | 1990-09-07 | 1994-02-08 | The Cleveland Clinic Foundation | Process for purifying and characterizing myotrophia, a novel peptide that regulates myocardial growth |
| EP0556331A4 (en) | 1990-11-09 | 1994-10-12 | Abbott Lab | AMPLIFIED HETEROGENIC CHEMILUMINESCENCE IMMUNOASSAY. |
| ATE229543T1 (de) | 1991-06-24 | 2002-12-15 | Chiron Corp | Polypeptide des hepatitis c-virus (hiv) |
| JPH06505803A (ja) | 1992-01-06 | 1994-06-30 | デイド、インターナショナル、インコーポレイテッド | マルチテスト免疫化学的試薬及びその使用方法 |
| JP3225468B2 (ja) * | 1992-08-28 | 2001-11-05 | ダイナボット株式会社 | 抗体測定用試薬 |
| CN1105181A (zh) | 1993-04-14 | 1995-07-12 | 国际莫莱斯技术公司 | 免疫测定法 |
| KR100312534B1 (ko) * | 1993-04-28 | 2002-05-13 | 성재갑 | 씨(c)형간염및비(b)형간염동시측정면역블롯검정키트및면역블롯검정법 |
| AU6913394A (en) | 1993-05-13 | 1994-12-12 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nucleic acid tagged immunoassay |
| DE19502386A1 (de) * | 1995-01-26 | 1996-08-01 | Boehringer Mannheim Gmbh | Stabilisierung von Peptiden und Polypeptiden in immunologischen Tests durch Zusatz von kleinen Hitzeschockproteinen |
| US5705330A (en) | 1995-04-14 | 1998-01-06 | Abbott Laboratories | Chemiluminescent immunoassay for antibody detection |
| US5616460A (en) * | 1995-06-07 | 1997-04-01 | Abbott Laboratories | Buffer composition for reagents for immunoassay |
| JPH09127114A (ja) * | 1995-11-01 | 1997-05-16 | Dainabotsuto Kk | 免疫学的測定用安定化ＩｇＭ試薬 |
| ES2251028T3 (es) | 1996-05-24 | 2006-04-16 | Chiron Corporation | Proteina de fusion de epitopos multiples. |
| DE69840334D1 (de) * | 1997-09-22 | 2009-01-22 | Novartis Vaccines & Diagnostic | Puffern zur stabilizierung von hcv antigenen |
-
1998
- 1998-09-22 DE DE69840334T patent/DE69840334D1/de not_active Expired - Lifetime
- 1998-09-22 EP EP98948399A patent/EP1021723B1/en not_active Expired - Lifetime
- 1998-09-22 AU AU94980/98A patent/AU9498098A/en not_active Abandoned
- 1998-09-22 WO PCT/US1998/019694 patent/WO1999015901A1/en not_active Ceased
- 1998-09-22 JP JP2000513148A patent/JP4427182B2/ja not_active Expired - Lifetime
- 1998-09-22 US US09/158,815 patent/US6261764B1/en not_active Expired - Lifetime
- 1998-09-22 AT AT98948399T patent/ATE417275T1/de not_active IP Right Cessation
- 1998-09-22 CA CA002303165A patent/CA2303165C/en not_active Expired - Lifetime
- 1998-09-22 ES ES98948399T patent/ES2316171T3/es not_active Expired - Lifetime
-
2001
- 2001-02-02 US US09/775,962 patent/US6537745B2/en not_active Expired - Lifetime
-
2009
- 2009-05-21 JP JP2009123636A patent/JP2009180750A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU9498098A (en) | 1999-04-12 |
| WO1999015901A1 (en) | 1999-04-01 |
| US6261764B1 (en) | 2001-07-17 |
| ATE417275T1 (de) | 2008-12-15 |
| JP2009180750A (ja) | 2009-08-13 |
| CA2303165A1 (en) | 1999-04-01 |
| US20010039009A1 (en) | 2001-11-08 |
| JP2001517799A (ja) | 2001-10-09 |
| ES2316171T3 (es) | 2009-04-01 |
| EP1021723B1 (en) | 2008-12-10 |
| DE69840334D1 (de) | 2009-01-22 |
| US6537745B2 (en) | 2003-03-25 |
| EP1021723A1 (en) | 2000-07-26 |
| CA2303165C (en) | 2006-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4427182B2 (ja) | 抗原を安定化するための緩衝液 | |
| AU719929B2 (en) | Multiple epitope fusion protein | |
| US6514731B1 (en) | Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens | |
| US6596476B1 (en) | Hepatitis C assay | |
| RU2126158C1 (ru) | Способ обнаружения антител, способ скрининга компонентов крови, набор для обнаружения антител к hcv | |
| US5625034A (en) | Core antigen protein of hepatitis C virus, and diagnostic method and kit using the same | |
| EP0471356B1 (en) | Antigenic peptide for detecting anti-hepatitis C virus antibodies and use thereof | |
| EP0642666B1 (en) | Hepatitis c assay | |
| US6391540B1 (en) | Method for detecting antibodies in a sample | |
| US20030170618A1 (en) | Buffers for stabilizing antigens | |
| EP1978365B1 (en) | Reagent kit and method for measuring HCV antibody | |
| JP2008261841A (ja) | Ｈｃｖ抗体測定用試薬キット及びｈｃｖ抗体測定方法 | |
| JP4975600B2 (ja) | Ｈｃｖ抗体測定用試薬キット及びｈｃｖ抗体測定方法 | |
| EP0624597B1 (en) | HCV peptides and uses thereof | |
| JPH06213895A (ja) | Ｃ型肝炎の急性期の決定方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050622 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060106 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20080514 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080519 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080819 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081121 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090220 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090227 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090317 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090325 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090420 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090427 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091130 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091214 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121218 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121218 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131218 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |